Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

A Phase I, Open-label, Multi-center, First-in-human Trial to Investigate E303, in Participants with Advanced Refractory Solid Tumors Under evaluation

2025-524192-24-00 advanced refractory solid tumors
FusionVAC22_01: DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocel… Not authorised

2022-502869-17-00 tumor entities carrying the oncogenic driver fusion DNA
A two part, randomized, double-blind, placebo-controlled, parallel group SAD and MD clinical study to evaluate the safety, tolerability and … Not authorised

2022-503145-22-00 Pseudomonas colonization
A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors Not authorised

2023-503170-20-00 Advanced solid tumors
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Not authorised

2023-503909-11-00 Ovarian cancer
First administration in healthy volunteers of a single and increasing dose of a new molecule for the treatment of brain diseases Not authorised

2023-505030-99-00 Post-Traumatic Stress Disorder (PTSD)
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a pDNA Vaccine Candidate Against COVID-19 in Healthy Adults Not authorised

2023-505135-12-00 Covid-19 Prophylaxis
A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER Not authorised

2023-508058-24-00 LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLOREC
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study) Not authorised

2023-508444-22-00 Chronic hepatitis B infection
CRISPR-TIL for metastatic melanoma Not authorised

2023-510417-25-00 Advanced or metastatic melanoma
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics… Not authorised

2024-512106-26-00 Cognitive impairment
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors pr… Not authorised

2024-512403-39-00 Advanced Solid Tumors Who Are Beyond Standard of Care
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacody… Not authorised

2024-516660-28-00 Locally advanced, recurrent, or metastatic breast, gast
Phase I, single and multiple ascending dose, randomized, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the saf… Not authorised

2024-518758-18-00 Diabetic retinopathy.
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors Not authorised

2024-519862-33-00 Platinum-resistant ovarian cancer (PROC)
KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer Not authorised

2022-501854-12-00 KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma
A study to test how either a capsule or a tablet with NDec (Decitabine and Tetrahydrouridine) works in the body of healthy people Not authorised

2023-504582-22-00 Sickle Cell Disease
An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging p… Pending

2023-506965-72-00 Parkinson Disease
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic, adenoid cystic carcinoma… Pending

2023-508476-11-00 Adenoid cystic carcinoma (ACC)
A study evaluating the safety, tolerability, pharmacokinetics, and activity of RO7566802 given alone and in combination with atezolizumab in… Pending

2023-509266-38-00 Locally Advanced or Metastatic Solid Tumors
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle… Pending

2023-509729-33-00 Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
E. coli Urinary Tract Infection Study Pending

2023-509777-23-00 Bacterial urinary infection
Evaluation of safety of somatic cell based therapy for urinary incontinence in patients after radical prostatectomy, open trial. Pending

2023-509812-27-01 urinary incontinence
Phase Ia/Ib Study of UBX-303061 in Subjects with Relapsed/Refractory B-Cell Malignancies Pending

2023-510484-35-00 B-cell malignancies